<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01864772</url>
  </required_header>
  <id_info>
    <org_study_id>GORTEC ELAN-FIT</org_study_id>
    <nct_id>NCT01864772</nct_id>
  </id_info>
  <brief_title>Phase II Trial of Carboplatin, 5-FU and Cetuximab in Elderly Fit (no Frailty) Patients With Recurrent/Metastatic HNSCC</brief_title>
  <acronym>ELANFIT</acronym>
  <official_title>Phase II Multicenter Trial Evaluating First Line Carboplatin, 5-Fluorouracil and Cetuximab in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Cancer, Aged 70 and Over, Ranked as Fit (no Frailty) by Geriatric Assessment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Groupe Oncologie Radiotherapie Tete et Cou</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gustave Roussy, Cancer Campus, Grand Paris</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Groupe Oncologie Radiotherapie Tete et Cou</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the trial is to evaluate the clinical benefit (efficacy, safety, preservation of&#xD;
      autonomy) of cetuximab-carboplatin-5FU combination as first line treatment of recurrent or&#xD;
      metastatic head and neck squamous cell carcinoma in patients over 70 years without frailty&#xD;
      (after geriatric assessment).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 2013</start_date>
  <completion_date type="Actual">May 26, 2020</completion_date>
  <primary_completion_date type="Actual">April 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response and acute toxicity</measure>
    <time_frame>1 month after the end of chemotherapy</time_frame>
    <description>Objective tumor response at 12 weeks, safety (no grade 3, 4, 5 toxicities) and preservation of geriatric autonomy (absence of 2 or more points decrease on the Activities of Daily Living (ADL) scale) 1 month after the end of chemotherapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Best objective tumor response</measure>
    <time_frame>6 weeks after the end of treatment</time_frame>
    <description>Best objective tumor response during treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>1 year after the end of treatment</time_frame>
    <description>Overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>progression free survival</measure>
    <time_frame>1 year after the end of treatment</time_frame>
    <description>progression free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response under cetuximab maintenance therapy</measure>
    <time_frame>1 year after the end of maintenance</time_frame>
    <description>Duration of response under cetuximab maintenance therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity of cetuximab maintenance therapy</measure>
    <time_frame>3 months after the end of maintenance</time_frame>
    <description>Toxicity of cetuximab maintenance therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>autonomy</measure>
    <time_frame>1 month after the end of treatment</time_frame>
    <description>Autonomy assessed by ADL and IADL scales during treatment and until 1 month after the end of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health related quality of life</measure>
    <time_frame>1 month after the end of chemotherapy</time_frame>
    <description>Quality of life assessed by EORTC QLQ-C30 and QLQ-HN35 questionnaires</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">85</enrollment>
  <condition>Metastatic or Recurrent Head and Neck Squamous Cell Cancer</condition>
  <arm_group>
    <arm_group_label>Carbo, 5FU, Cetuximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 cycles (1 cycle = 21 days) of: carboplatin AUC 5, 5FU D1-4 1000mg/m²/d, every 21 days cetuximab weekly (400 mg/m² the first week of treatment and then 250 mg/m²/w)&#xD;
Maintenance by cetuximab 500 mg/m² every 2 weeks until progression or toxicity</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carbo, 5FU, Cetuximab</intervention_name>
    <description>6 cycles (1 cycle = 21 days) of: carboplatin AUC 5, 5FU D1-4 1000mg/m²/d, every 21 days cetuximab weekly (400 mg/m² the first week of treatment and then 250 mg/m²/w)&#xD;
Maintenance by cetuximab 500 mg/m² every 2 weeks until progression or toxicity</description>
    <arm_group_label>Carbo, 5FU, Cetuximab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age greater than or equal to 70 years&#xD;
&#xD;
          -  patient enrolled in ELAN-ONVOCAL study and evaluated as fit (harmonious aging) by&#xD;
             GERICO screening method for geriatric frailty&#xD;
&#xD;
          -  life expectancy superior to 12 weeks&#xD;
&#xD;
          -  creatinin clearance &gt; ou equal to 50ml/mn calculated using Modification of Diet in&#xD;
             Renal Disease (MDRD) formula&#xD;
&#xD;
          -  hematologic function : absolute neutrophil count &gt; 1.5 x 10^9/l, platelets &gt; 100 x&#xD;
             10^9/l, hemoglobin &gt; 9,5 g/dl&#xD;
&#xD;
          -  liver function : total bilirubin inferior to 1,25 x Upper limit of normal (ULN),&#xD;
             SGOT/SGPT inferior to 5 x ULN, PAL inferior to 5 x ULN&#xD;
&#xD;
          -  PS &lt; 2&#xD;
&#xD;
        The disease:&#xD;
&#xD;
          -  histologically proven head and neck squamous cell carcinomas&#xD;
&#xD;
          -  recurrent or metastatic. Visceral metastases or locoregional recurrence unsuitable for&#xD;
             curative locoregional treatment: unsuitable for primitive tumor surgery due to local&#xD;
             extension (evidently authorized for lymph nodes) and unsuitable for radiotherapy for&#xD;
             primitive tumor (or already performed) due to metastatic dissemination and the absence&#xD;
             of indication for re-irradiation of primitive tumor.&#xD;
&#xD;
          -  Presence of at least one measurable lesion (defined by RECIST criteria) by CT scan or&#xD;
             IRM&#xD;
&#xD;
          -  asymptomatic cerebral metastases authorized&#xD;
&#xD;
        General:&#xD;
&#xD;
          -  signed Informed Consent Form&#xD;
&#xD;
          -  affiliated to the French social security system (or a beneficiary of this system)&#xD;
             according to the provisions of the law of 9 August 2004&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous systemic chemotherapy, except for chemotherapy as part of multimodal&#xD;
             treatment for locally advanced cancer completed more than 6 months prior to study&#xD;
             enrollment&#xD;
&#xD;
          -  Known contraindication specific to one of study treatments (particularly cardiac for&#xD;
             5FU)&#xD;
&#xD;
          -  Known dihydropyrimidine dehydrogenase deficiency (DPD deficiency).&#xD;
&#xD;
          -  Patients considered as &quot;unfit &quot; (fragile) by GERICO screening method for geriatric&#xD;
             frailty&#xD;
&#xD;
          -  Irradiation within 4 weeks prior to study enrollment.&#xD;
&#xD;
          -  Nasopharyngeal, rhinopharyngeal or maxillary sinus carcinoma.&#xD;
&#xD;
          -  Presence of infection (infection requiring intravenous antibiotics), including&#xD;
             tuberculosis and HIV infection (human immunodeficiency virus).&#xD;
&#xD;
          -  Concomitant treatment with other antitumor immunotherapy or hormonal therapy.&#xD;
&#xD;
          -  Other antitumor concomitant therapies.&#xD;
&#xD;
          -  Prior treatment with EGFR-targeted therapy (epidermal growth factor receptor).&#xD;
&#xD;
          -  Treatment with one of study drugs within 30 days prior to study enrollment.&#xD;
&#xD;
          -  Presence of documented symptomatic brain or leptomeningeal metastases&#xD;
&#xD;
          -  Clinically significant coronaropathy or antecedent myocardial infarction within 12&#xD;
             months prior to study enrollment or high-risk uncontrolled arrhythmias or uncontrolled&#xD;
             heart failure.&#xD;
&#xD;
          -  Medically uncontrolled arterial hypertension&#xD;
&#xD;
          -  Other prior or concomitant cancer, with exception for carcinoma in situ of the uterine&#xD;
             cervix, or for cutaneous basal cell carcinoma within 5 years prior to study&#xD;
             enrollment.&#xD;
&#xD;
          -  Presence of medical or physiological factors susceptible to modify patient compliance&#xD;
             with study protocol and follow-up or Informed Consent Form signing.&#xD;
&#xD;
          -  Known allergy or hypersensibility to monoclonal antibodies (bevacizumab, cetuximab),&#xD;
             or to other chemotherapies of the study or to their excipients&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>70 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hôpital de la Dracénie</name>
      <address>
        <city>Draguignan</city>
        <zip>83300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www.gortec.fr/</url>
    <description>GORTEC</description>
  </link>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>May 21, 2013</study_first_submitted>
  <study_first_submitted_qc>May 24, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 30, 2013</study_first_posted>
  <last_update_submitted>April 8, 2021</last_update_submitted>
  <last_update_submitted_qc>April 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HNSCC</keyword>
  <keyword>Metastatic</keyword>
  <keyword>Recurrent</keyword>
  <keyword>Elderly</keyword>
  <keyword>Geriatry</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms, Squamous Cell</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Frailty</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

